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Available online xxxxBackground:Urinary tract infections (UTIs) aremajor drivers of antibiotic prescribing in primary care. Inappropri-
ate antibiotic prescribing for UTIs likely drives antibiotic resistance. We aimed to describe current investigation
and antibiotic treatment to examine opportunities for improved antimicrobial stewardship.
Methods:We identiﬁed a cohort of all patients with lower UTI diagnosis between 2011 and 2015 in the 390 pri-
mary care practices contributing data to ResearchOne in England. We examined investigation, antibiotic treat-
ment and antibiotic re-prescription within 28 days according to guideline-deﬁned patient groups. We assessed
risk factors for re-prescription using mixed-effect logistic regression.
Findings: In total, 494,675 UTIs were diagnosed in 300,354 patients. Median age was 54 years, and 83.3% were
women. Same-day antibiotic was prescribed for 85.7% of UTIs; 56.8% were treated with trimethoprim, and
urine samplingwas undertaken in 25.0%. The antibiotic re-prescription ratewas low (17,430, 4.1%) and increased
slightly over time in men (from 5.2% in 2011 to 6.2% in 2015). Overall, 21.1% of pre-prescription were for the
same antibiotic. The percentage of adults with recurrent UTIs ranged from 1.0% in 18–64 year-old men to 2.6%
in women ≥65 years. The risk of antibiotic re-prescription increased with age, calendar year, recent antibiotic
prescribing and treatment with antibiotic other than trimethoprim or nitrofurantoin.
Interpretation: Most patients diagnosed with lower UTI in primary care receive same-day empirical antibiotics
with little diversity in choice of agent. The antibiotic re-prescription rate is low. Microbiological investigation
and re-prescription of the same antibiotic given for the initial episode happened in one quarter of UTIs.
Funding: UK National Health Service Improvement.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Diversity1. Introduction
Symptoms of urinary tract infection (UTIs) are a common reason for
consultation in primary care, where most suspected episodes are man-
aged. Uncomplicated lower UTIs generally resolve quickly andmany are
self-limiting [1], but 11% of women report to have experienced at least
one UTI and 3% report to have experienced three or more UTIs in the
previous year [2]. There are marked differences across four European
countries in culture positivity, antibiotic prescribing and re-
consultation, despite similarities in the presentation of UTI in primary
care, the pathogens and antibiotic sensitivities [3]. The high incidence
of UTI and tendency to recur leads to high healthcare costs [4].
UTIs are the second most common reason for antibiotic prescribing
[5]. In the UK, recent national clinical guidelines recommend treatmentSciences, University of Leeds,
(M. Pujades-Rodriguez).
en access article under the CC BY-NC
ez, R.M. West, M.H.Wilcox, e
s://doi.org/10.1016/j.eclinm.of lower UTIs with narrow spectrum antibiotics, particularly
nitrofurantoin or trimethoprim, when the risk of resistance is low (e.g.
considering previous antibiotic use and previous urine culture and sen-
sitivity results) [6]. Amoxicillin or oral cephalosporins are advised for
second or third line therapy for pregnant women and children aged
3 months or more [6]. Choice of second line antibiotic therapy in adult
men should be guided by culture results after considering alternative di-
agnoses to UTIs [6]. Antibiotic use, even in short courses, can alter the
normal microbial composition of the gastrointestinal tract and the va-
gina [7], selecting for drug-resistant pathogens. Furthermore, a meta-
analysis of ﬁve studies of UTIs managed in primary care found an in-
creased risk of antibiotic resistance that persisted for up to one year
and a higher risk associated with multiple courses of antibiotics [8]. Ev-
idence of a dose–response between the number of courses of amoxicil-
lin and trimethoprim and resistance also exists [9]. Antibiotic resistance
is associatedwith highermorbidity, mortality and healthcare costs [10].
It is therefore important to avoid unnecessary antibiotic prescribing and
to make appropriate choices to treat UTIs.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
Urinary tract infections (UTIs) are major drivers of antibiotic
prescribing in primary care. Inappropriate antibiotic prescribing
for UTIs likely drives antibiotic resistance. PubMed was searched
for publications reporting on treatment failure rates and risk fac-
tors in patients treated for lower urinary tract infection up to Feb-
ruary 6, 2018. Search terms were (“urinary tract
infections”[Mesh] AND (“treatment failure”[Mesh] OR ((“ther-
apy” OR “treatment” OR “therapeutics”[MeSH Terms]) AND re-
sponse AND failure))) with no language restriction. Of 157
articles retrieved, 6 were identiﬁed as relevant. The most recent
period studied was 2013–2017 in a multinational clinical trial in-
cluding 513women. Reported rates varied between 2%when fail-
ure requiring hospitalisation was studied in Taiwan, to 39%
amongst women treated with fosfomycin in a multinational clin-
ical trial in hospital units and outpatient services. Treatment fail-
ure was found to be associated with older age, pregnancy,
diabetes, renal impairment, antibiotic choice and duration. We
concluded that few studies have examined the frequency of, and
risk factors for treatment failure across the spectrumof UTI, or de-
scribed its management in the community.
Added value of this study
Most patients diagnosed with lower UTI in primary care
(85.7%) receive same-day empirical antibiotic therapy with little
treatment diversity, generally limited to trimethoprim and
nitrofurantoin, reﬂecting national guidelines. Microbiological in-
vestigation was undertaken infrequently and had little impact
on treatment. The antibiotic re-prescription rate was low (4.1%)
but gradually increased over time and was seen on average in
over 3000 patients each year. Re-prescription of the same antibi-
otic occurred surprisingly frequently.
Implications of all the available evidence
Guidelines for investigation of UTI are not being followed. Use
of microbiological investigations currently has little impact on
prescribing. There is a need to consider recent antibiotic use to
prevent re-prescription of the same antibiotic.
2 M. Pujades-Rodriguez et al. / EClinicalMedicine xxx (xxxx) xxxThis study aimed to describe current investigation, antibiotic treat-
ment and antibiotic re-prescription rates (as a likely indicator of treat-
ment failure) across the spectrum of all lower urinary tract infections
(UTIs) managed in primary care in England, with reference to current
guideline-deﬁned groups of patients.
2. Methods
2.1. Study Design and Setting
We analysed a cohort of all patients attending primary care general
practices contributing data to ResearchOne. ResearchOne is a healthcare
research database containing de-identiﬁed clinical and administrative
data drawn from the electronic patient health records held on The Phoe-
nix Partnership (TPP) SystmOne clinical record system. ResearchOne
was created by TPP in partnership with the University of Leeds and
the UK Government's Technology Strategy Board. It contains approx-
imately 28 million records from over 400 general practitioners' prac-
tices spread geographically throughout England and is updated from
new data entered as part of routine clinical practice on TPP
SystmOne. Primary care clinical data are coded using the ReadPlease cite this article as: M. Pujades-Rodriguez, R.M. West, M.H.Wilcox, e
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using the British National Formulary and the Dictionary of Medicines
and Drugs. Data quality checks are performed centrally to assess data
integrity, quality and representativeness of the population in En-
gland (http://www.researchone.org/data/). The data extract
analysed was created on 5 June 2017. The study period was from 1
January 2011 to 31 December 2015. For each patient, we analysed in-
formation from the general practice at which the patient had most
recently been registered.
The studywas approved by the ResearchOne Project Committee and
the University of Leeds, Medicine and Health University Ethics Review
Committee (MREC-18-005). No patients or public were involved in
this research.
2.2. Study Participants
We identiﬁed all patients who had a lower UTI diagnostic code re-
corded during the study period. The diagnostic codes considered are
shown in Table S1. Individuals were eligible for study inclusion if they
were registered in a ResearchOne general practice for a minimum of
28 days before the date of UTI diagnosis. To ascertain the outcomes, a
minimum of 10 days of post-UTI follow-upwas also required. The eligi-
bility for study inclusion ended on the earliest of the following dates:
death, practice deregistration or last date of data collection from the
practice.
2.3. Study Deﬁnitions
The diagnostic codes used to identify episodes of lower UTI are listed
in Supplementary Table 1. To account for multiple consultations for the
same episode of infection, we considered diagnostic codes recorded
within 28 days of each other to be related to the same UTI episode (Sup-
plementary Fig. 1A). The index date of a UTI episode was deﬁned by the
date of the ﬁrst recorded UTI diagnostic code for that episode in the pa-
tient record [11,12]. We excluded episodes that started prior to 1st Jan-
uary 2011. Patients with UTI were grouped into 7 groups deﬁned
according to recent clinical guidelines [13] (Table 1).
To describe the proportion of patients who had a urine sample col-
lected for culture ormicroscopy during the index episode, we identiﬁed
Read codes for either requests or results that were recorded within
10 days of the UTI start date (Supplementary Table 2). To describe the
number of patients who received antimicrobial therapy for UTI whilst
allowing for delays related to microbiological diagnosis [14], we identi-
ﬁed prescriptions for any oral antibiotic issued on the same day or
within 3 days of the index UTI diagnosis (British National Formulary
[BNF] chapter 1.5; Supplementary Table 3).
As in previous studies [15], we studied antibiotic re-prescription as a
proxy measure of treatment effectiveness. We deﬁned antibiotic re-
prescription as the earliest prescription of a UTI-speciﬁc antibiotic for
the same UTI episode between 4 and 28 days after the date of the initial
antibiotic prescription (Supplementary Fig. 1B). These antibiotics in-
cluded drugs recommended, or used for the treatment of UTIs in the
UK, albeit not necessarily exclusively for this purpose (trimethoprim,
nitrofurantoin, pivmecillinam, fosfomycin, ciproﬂoxacin, cephalexin,
and co-amoxiclav). For sensitivity analyses, we also deﬁned antibiotic
re-prescription as the earliest occurrence of a new antibiotic prescrip-
tion of a UTI-speciﬁc antibiotic between 6–28 days and 8–28 days
after the initial antibiotic prescription. Information on antibiotic suscep-
tibility, prescription duration and reason for antibiotic regimen were
not available in this setting. Drug allergy and intolerancewere discarded
as a reason for re-prescription in this study.
2.4. Statistical Analysis
For each patient group, we described the number of UTI episodes re-
corded and patient characteristics on the date of diagnosis. We alsot al., Lower Urinary Tract Infections: Management, Outcomes and Risk
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Table 1
Patient characteristics at diagnosis of lower urinary tract infection by patient group.
Children b
3mths
Children 3
mths-3 yrs
Children
4–15 yrs
Women
18–64 yrs
Men 18–64
yrs
Adults ≥65
yrs
Pregnant
women
Catheter All UTIs
No. of patients 120 8491 23,392 144,096 22,629 100,393 1306 33 300,354
Total no. of episodes 121 10,015 30,868 229,883 29,559 184,725 1352 34 494,675
Median no. of episodes per patient [IQR] 1 [1–1] 1 [1–2] 1 [1–2] 2 [1–4] 1 [1–2] 2 [1–5] 1 [2–3] 2 [1–4] 2 [1–4]
Median age in years [IQR] NA 2 [2–3] 8 [5–11] 41 [29–53] 50 [40–58] 77 [71–84] 28 [24–32]
73
[63–83]
54 [31–73]
Women, n (%) 51 (42.2)
7645
(76.3)
26,366
(85.4)
NA NA
137,572
(74.5)
NA 6 (17.7)
410,667
(83.0)
Ethnicity, n (%)
White 53 (76.8)
6446
(83.9)
15,730
(72.2)
135,022
(73.4)
16,221
(70.8)
115,794
(83.1)
770 (67.1) 20 (83.3)
293,694
(76.9)
Black 1 (1.5) 83 (1.1) 312 (1.4) 2316 (1.3) 366 (1.6) 356 (0.3) 26 (2.3) – 3493 (0.9)
Asian 8 (11.6) 728 (9.5) 2338 (10.7) 11,552 (6.3) 1558 (6.8) 2251 (1.6) 123 (10.7) – 18,700 (4.9)
Other 7 (10.1) 423 (5.5) 3416 (15.7)
35,127
(19.1)
4758 (20.8)
20,920
(15.0)
229 (20.0) 4 (16.7)
66,004
(17.3)
Calendar year, n (%)
2011 17 (14.1)
1701
(17.0)
5226 (16.9)
39,542
(17.2)
5317 (18.0)
32,571
(17.6)
255 (18.9) –
86,033
(17.4)
2012 28 (23.1)
1881
(18.8)
5827 (18.9)
43,364
(18.9)
5698 (19.3)
35,404
(19.2)
252 (18.6) –
93,903
(19.0)
2013 23 (19.0)
2023
(20.2)
6224 (20.2)
46,328
(20.2)
6032 (20.4)
37,185
(20.1)
273 (20.2) 2 (5.9)
99,663
(20.2)
2014 32 (26.5)
2284
(22.8)
6814 (22.1)
49,893
(21.7)
6183 (20.9)
39,410
(21.3)
285 (21.1) 12 (35.3)
106,745
(21.6)
2015 21 (17.4)
2126
(21.2)
6777 (22.0)
50,756
(22.1)
6329 (21.4)
40,155
(21.7)
287 (21.2) 20 (58.8)
108,331
(21.9)
Prior antibiotic use, n (%)
Prescribed in last year, n (%) 20 (16.5)
6060
(60.5)
16,699
(54.1)
146,582
(63.8)
16,102
(54.5)
138,900
(75.2)
793 (58.7) 24 (70.6)
329,980
(66.7)
Median time since last prior antibiotic in
months [IQR]
0.6
[0.3–0.9]
4.0
[1.3–9.9]
6.2
[2.0–14.7]
4.9
[1.7–11.7]
4.4
[1.2–12.8]
2.8 [1.0–7.8]
4.9
[1.8–12.3]
1.8
[0.8–5.1]
3.9
[1.3–10.4]
Comorbidities, n (%)
Cardiovascular diseases – 3 (0.03) 12 (0.04) 5464 (2.4) 2699 (9.1)
58,535
(31.7)
1 (0.1) 14 (41.2)
66,733
(13.5)
Diabetes – 4 (0.04) 132 (0.4) 12,502 (5.4) 3858 (13.1)
36,099
(19.5)
12 (0.9) 10 (29.4)
52,659
(10.7)
Asthma 1 (0.8) 237 (2.4) 3714 (12.0)
42,543
(18.5)
4359 (14.7)
24,777
(13.4)
236 (17.5) 2 (5.9)
77,463
(15.7)
COPD – 1 (0.01) 3 (0.01) 19 (0.01) 7 (0.02) 124 (0.1) – – 155 (0.03)
Cancer – 3 (0.03) 47 (0.2) 8076 (3.5) 1765 (6.0)
32,476
(17.6)
6 (0.4) 12 (35.3) 42,408 (8.6)
CKD stage 3–5 – 4 (0.04) 12 (0.04) 4355 (1.9) 1048 (3.6)
49,920
(27.0)
1 (0.1) 4 (11.8)
55,351
(11.2)
Note: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; UTI, urinary tract infection. Ethnicity was missing for 22.8% of episodes of UTI.
3M. Pujades-Rodriguez et al. / EClinicalMedicine xxx (xxxx) xxxdetermined the proportion of episodes for which a urine sample for cul-
ture ormicroscopywas collected, the annual number of UTIs per patient
and the proportion treated (antimicrobial therapy, ﬁrst drug class and
multiple antibiotics). Furthermore, we described the proportion of
UTIs managed with antibiotic re-prescription each year and their treat-
ment. For patients treated with antibiotics, we also described patient
baseline characteristics according to whether they resulted in re-
prescription or not, and investigated risk factors for antibiotic re-
prescription usingmixed effect logistic regressionmodels with GP prac-
tice and patient level randomeffects to account forwithin patient corre-
lation of events (i.e. all UTI episodes diagnosed for each patient were
analysed) and heterogeneity between practices. A priori factors consid-
ered and included in adjusted regression models were risk factors for
UTI reported in previous studies that were available and likely to be
well coded: age (b10, 10-year groups between 10–79 and ≥80 years),
sex, ethnicity (missing data recorded as a separate category), year of
UTI diagnosis, diagnosed chronic comorbidities (cardiovascular dis-
eases, diabetes, chronic obstructive pulmonary disease, asthma, cancer
and chronic kidney disease of stage ≥3 recorded before theUTI episode),
antibiotic/s use in last year (none, b1 month, 1 to b3 months, 3 to b
6months, 6 to b12months), and the initial antibiotic prescribed. Statis-
tical tests were 2-sided, and statistical signiﬁcance was considered p b
0.05. All analyses were performed in Stata version 15.0 (StataCorp LP,
College Station, TX, USA).Please cite this article as: M. Pujades-Rodriguez, R.M. West, M.H.Wilcox, e
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The study funder had no role in study design, data collection, analy-
sis, interpretation, orwriting up of the report. The corresponding author
had full access to all the data and had ﬁnal responsibility for the decision
to submit for publication.
2.6. Data Statement
Access to raw data can be requested from the The Phoenix Partner-
ship (TPP) SystmOne clinical system (http://www.researchone.org/
data/).
3. Results
3.1. UTI Diagnosis and Patient Characteristics
During the study period, a total of 494,675 episodes were recorded
as lower UTI in 300,354 patients registered in 390 general practices
(mean 1.7 infections per person). Eighty-three per cent of episodes
were in women (Table 1). Median age at diagnosis was 54 years (IQR
31–73). The highest frequency of UTIs occurred in women aged
18–64 years (46.5%) and the lowest amongst children of b3 months oft al., Lower Urinary Tract Infections: Management, Outcomes and Risk
2019.07.012
4 M. Pujades-Rodriguez et al. / EClinicalMedicine xxx (xxxx) xxxage (9.1%). The overall mean annual number of UTI episodes per person
was 1 (SD=0.40). The percentage of adultswith only 1 UTI episode per
year ranged from 79.2% in women aged ≥65 years to 91.0% inmen aged
18–64 years (Fig. 1). The percentage of adults with ≥3 episodes per year
(recurrent UTI) ranged from 1.0% in men aged 18–64 years to 2.6% in
women aged ≥65 years.
An antibiotic prescription for any indication in the previous yearwas
recorded for 66.7% of patientswith UTIs. Themedian time since last pre-
scribed antibiotic was 3.9 months (IQR 1.3–10.4), ranging from 0.6 for
children of b3 months to 6.2 months for those aged 4–15 years. A pen-
icillin (6% co-amoxiclav, 0.5% pivmecillinam, and 29.4% other penicillin),
trimethoprim (26.2%) and nitrofurantoin (15.1%)were thosemost often
prescribed. The most common comorbidities present at the time of UTI
diagnosis were asthma (15.7%) and cardiovascular diseases (13.5%).
Chronic kidney disease was also common in the eldest age group
(26.1% of episodes with stage 3 renal disease). A urine sample for mi-
croscopy or culture was requested within 10 days for 25.0% of episodes
(range between 9.1% in children of b3 months and 30.6% in 18- to 64-
year-old men; Table 2).
3.2. Antibiotic Treatment
Antibiotics were prescribed on the same date of diagnosis for 85.7%
of UTIs (range from 20.7% in children of b3 years to 89% in women
aged 18–64 years). Only 17% of thosewho received antibiotics had a re-
corded urine testing within 10 days of diagnosis (range from 9.1% for
the b3 year group to 30.6% for 18- to 64-year-old women). Overall,
the most common antibiotics initially prescribed were trimethoprim
(56.8%) and nitrofurantoin (23.9%; Fig. 2). Cephalexin was the most
commonly prescribed antibiotic in pregnant women (30.4%) and the
second most commonly prescribed in children aged b4 years (24.0% in
those b3 months and 5.6% in those aged 3 months to 3 years). Multiple
antibioticswere administered to 3543 (0.8%) patients. Six percent of UTI
episodes diagnosed in pregnantwomen (n=62)were treatedwith tri-
methoprim and the proportion of UTIs treatedwith co-amoxiclav varied
between 4.3% in children aged 4–15 years (n = 1086) and 7.6% in men
aged 18–64 years (n= 1830). Chronic kidney disease (of stage ≥3)was
diagnosed in 9.4% of episodes treatedwith nitrofurantoin inwomen and
15.0% of those in men (in 0.6 of episodes in women and 1.9% of those in
men with stage ≥4).
The ratio of trimethoprim to nitrofurantoin prescribing gradually de-
creased over the study period from 6317/1981 in 2011 to 7870/3481 in
2015 for men (28.1% decrease); and from 36,372/12,853 to 43,383/
24,099 (35.7% decrease), respectively, in women (SupplementaryFig. 1. Distribution of patients by the annual number of lower urinary tra
Please cite this article as: M. Pujades-Rodriguez, R.M. West, M.H.Wilcox, e
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with trimethoprim slightly decreased over time, from 45.9% in 2011 to
43.4% in 2015. The absolute number of UTIs diagnosed in this patient
group increased during the study period, from 8938 in 2011 to 10,264
in 2015. In men, this number also increased over time (from 2657 to
3314, respectively), but the proportion of episodes treated with tri-
methoprim remained stable during the study period (overall 40.2%).3.3. Antibiotic Re-prescription
Antibiotic re-prescription occurred in 17,430 (4.1%) UTI episodes
treated with antibiotics, ranging from 1.9% in children aged
4–15 years and in pregnant women, to 6.3% in adults aged ≥65 years.
These re-prescription events were unrelated to antibiotic allergy or in-
tolerance (data not shown). Antibiotic re-prescription occurred in
9859 (6.3%) episodes diagnosed in ≥65-year-old adults and increased
slightly over time only in men (from 5.2% in 2011 to 6.2% in 2015).
When deﬁning antibiotic re-prescription using antibiotic prescribing
windows of 6–28 and 8–28 days (instead of 4–28), re-prescription
was observed in 14,972 (3.5%) and 11,912 (2.8%) of UTI episodes, re-
spectively (Supplementary Table 4). Factors associated with antibiotic
re-prescription are shown in Table 3. The risk increased with age,
from 2.1% of episodes in patients b10 years to 6.9% of episodes in
those aged ≥80 years (adjusted odds ratio [OR] = 0.97, 95%CI 0.84 to
1.12 for 10–19 years and 2.62, 95%CI 2.34 to 2.94 for those ≥80 years,
compared with UTI episodes from patients aged b10 years; p b 0.001).
Odds of infection was lower in women than in men (OR = 0.77, 95%CI
0.73 to 0.80; p b 0.001) and in non-white ethnic groups (OR = 0.61,
95%CI 0.45–0.83 for black; OR = 0.75, 95%CI 0.67–0.85 for Asian; com-
pared towhite). It was slightly higher in patientswith comorbidities, in-
cluding cancer (OR = 1.15, 95%CI 1.09 to 1.21; p b 0.001) and diabetes
(OR = 1.12, 95%CI 1.07 to 1.18; p b 0.001). Odds of re-prescription in-
creased with shorter time since prior antibiotic use, from 1.16 (95%CI
1.09 to 1.24) for 6–12 months to 3.35 (95%CI 3.19 to 3.53) for
b 1 month, compared with non-use in the previous year (p b 0.001).
Initial treatment of the UTI with antibiotics other than trimethoprim
was associated with a higher odds of re-prescription (OR = 1.18, 95%
CI 1.10 to 1.27 for co-amoxiclav; OR = 1.56, 95%CI 1.30 to 1.86 for
pivmecillinam; OR= 8.98, 95%CI 8.18 to 9.85 for multiple concomitant
antibiotics; compared with trimethoprim) except for nitrofurantoin
(OR = 0.96, 95%CI 0.92 to 1.00). Furthermore, the odds of re-
prescription of any antibiotic increased over time (OR = 1.20, 95%CI
1.14 to 1.27 in 2015 compared with 2011; p b 0.001).ct infection episodes in adult women and men, Jan 2011–Dec 2015.
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Table 2
Diagnosis and treatment of episodes of lower urinary tract infection by patient group.
Children
b
3mth
Children
3mth–3
yrs
Children
4–15
yrs
Women
18–64
yrs
Men 18–64
yrs
Adults ≥65
yrs
Pregnant
women
Catheter All UTIs
No. of patients 120 8491 23,392 144,096 22,629 100,393 1306 33 300,354
Total no. of episodes 121 10,015 30,868 229,883 29,559 184,725 1352 34 494,675
Urine testing within 10 days, n (%) 11 (9.1)
2624
(26.2)
9426 (30.5) 54,235 (23.6) 9036 (30.6) 45,978 (24.9) 301 (22.3) 7 (20.6)
123,409
(25.0)
No. of antibiotics prescribed, n (%)
0 91 (75.2)
3034
(30.3)
5174 (16.8) 22,016 (9.6) 5209 (17.6) 28,634 (15.5) 316 (23.4)
17
(50.0)
65,414 (13.2)
1 29 (24.0)
6928
(69.2)
25,532
(82.7)
206,222
(89.7)
24,153
(81.7)
154,331
(83.6)
1031
(76.3)
17
(50.0)
425,399
(86.0)
2 1 (0.8) 51 (0.5) 160 (0.5) 1611 (0.7) 192 (0.7) 1723 (0.9) 5 (0.4) – 3782 (0.8)
3+ – 2 (0.02) 2 (0.01) 34 (0.01) 5 (0.02) 37 (0.02) – – 80 (0.02)
Antibiotic prescribed on date of diagnosis, n
(%)
25 (20.7)
6786
(67.8)
25,354
(82.1)
206,094
(89.7)
24,022
(81.3)
153,520
(83.1)
1008
(74.6)
17
(50.0)
423,967
(85.7)
Trimethoprim 13 (52.0)
4709
(69.4)
19,222
(75.8)
117,450
(57.0)
13,671
(56.9)
80,745 (52.6) 62 (6.2) 8 (47.1)
240,797
(56.8)
Nitrofurantoin – 113 (1.7) 1242 (4.9) 53,954 (26.2) 4844 (20.2) 39,413 (25.7) 254 (25.2) 7 (41.2)
101,205
(23.9)
Cephalexin 6 (24.0) 380 (5.6) 1231 (4.9) 10,551 (5.1) 1039 (4.3) 8303 (5.4) 306 (30.4) – 22,032 (5.2)
Co-amoxiclav 1 (4.0) 375 (5.5) 1086 (4.3) 7680 (3.7) 1813 (7.6) 8880 (5.8) 48 (4.8) 1 (5.9) 20,104 (4.7)
Ciprofoxacin – 7 (0.1) 58 (0.2) 2353 (1.1) 1083 (4.5) 3671 (2.4) – – 7215 (1.7)
Pivmecillinam – 1 (0.01) 18 (0.1) 626 (0.3) 76 (0.3) 1249 (0.8) 1 (0.1) – 1985 (0.5)
Fosfomycin – – – 10 (0.0) 2 (0.01) 42 (0.03) – – 54 (0.01)
Other 5 (20.0)
1157
(17.1)
2350 (9.3) 11,933 (5.8) 1321 (5.5) 9617 (6.3) 333 (33.0) 1 (5.9) 27,032 (6.4)
Multiple – 44 (0.7) 147 (0.6) 1537 (0.8) 173 (0.7) 1600 (1.0) – – 3543 (0.8)
Antibiotic re-prescriptiona, n (%) 1 (3.3) 167 (2.4) 475 (1.9) 5638 (2.7) 1143 (4.7) 9859 (6.3) 20 (1.9) 4 (23.5) 17,430 (4.1)
Antibiotic prescribed for treatment failure, n
(%)
Nitrofurantoin – 19 (11.4) 122 (25.7) 2249 (39.9) 328 (28.8) 3134 (31.8) 7 (35.0) 1 (25.0) 5916 (33.9)
Trimethoprim – 51 (30.5) 107 (22.5) 1078 (19.1) 262 (23.0) 2350 (23.8) 2 (10.0) – 3873 (22.2)
Cephalexin – 51 (30.5) 125 (26.3) 757 (13.4) 117 (10.3) 1336 (13.6) 9 (45.0) – 2418 (13.9)
Co-amoxiclav – 41 (24.6) 92 (19.4) 808 (14.3) 168 (14.7) 1402 (14.2) 2 (10.0) 2 (50.0) 2530 (14.5)
Ciproﬂoxacin 1 (100) 2 (1.2) 15 (3.2) 438 (7.8) 211 (18.5) 1020 (10.4) – 1 (25.0) 1695 (9.7)
Pivmecillinam – – 5 (1.1) 133 (2.4) 21 (1.8) 289 (2.9) – 448 (2.6)
Fosfomycin – – – 8 (0.1) 3 (0.3) 22 (0.2) – – 33 (0.2)
Multiple – 3 (1.8) 9 (1.9) 168 (3.0) 31 (2.7) 306 (3.1) – – 517 (3.0)
a The number of antibiotic re-prescriptions has been calculated for patients who were prescribed an antibiotic for the index urinary tract infection episode within 3 days of diagnosis.
UTI, urinary tract infection.
Fig. 2. Distribution of the proportion of lower urinary tract infection episodes by type of antibiotic initially prescribed and patient group amongst patients with prescribed antibiotic, Jan
2011–Dec 2015.
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Table 3
Associations between patient characteristics at lower urinary tract infection diagnosis and antibiotic re-prescription amongst patients prescribed antibiotics.
UTI with re-prescription (%) UTI without re-prescriptiona (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)
No. of episodes 17,430 411,831
Sociodemographic characteristics
Women 13,505 (77.5) 349,004 (84.7) 0.59 (0.57–0.62) 0.77 (0.73–0.80)
Age group, years
b10 469 (2.7) 22,415 (5.4) 1 1
10–19 258 (2.6) 25,370 (6.2) 0.85 (0.74–0.97) 0.97 (0.84–1.12)
20–29 814 (4.7) 46,423 (11.3) 0.84 (0.75–0.95) 0.94 (0.83–1.07)
30–39 1050 (6.0) 44,498 (10.8) 1.13 (1.00–1.27) 1.26 (1.12–1.43)
40–49 1516 (8.7) 50,031 (12.2) 1.44 (1.28–1.61) 1.58 (1.40–1.77)
50–59 1856 (10.7) 49,531 (12.0) 1.80 (1.61–2.01) 1.81 (1.61–2.03)
60–69 3252 (18.7) 58,577 (14.2) 2.69 (2.42–2.99) 2.40 (2.15–2.69)
70–79 3819 (21.9) 58,089 (14.1) 3.22 (2.90–3.58) 2.59 (2.31–2.90)
≥80 4196 (24.7) 56,897 (13.8) 3.62 (3.26–4.02) 2.62 (2.34–2.94)
Ethnicityb
White 10,943 (81.4) 243,684 (76.4) 1 1
Black 51 (0.4) 2973 (0.9) 0.43 (0.32–0.58) 0.61 (0.45–0.83)
Asian 369 (2.7) 15,997 (5.0) 0.58 (0.51–0.65) 0.75 (0.67–0.85)
Other 2089 (15.5) 56,471 (17.7) 0.88 (0.82–0.95) 0.91 (0.85–0.97)
Calendar year
2011 2782 (16.0) 71,534 (17.4) 1 1
2012 3235 (18.6) 78,050 (19.0) 1.07 (1.01–1.13) 1.08 (1.02–1.15)
2013 3472 (19.9) 83,172 (20.2) 1.08 (1.02–1.14) 1.12 (1.05–1.18)
2014 3978 (22.8) 88,818 (21.6) 1.18 (1.12–1.25) 1.21 (1.15–1.28)
2015 3963 (22.7) 90,257 (21.9) 1.17 (1.11–1.24) 1.20 (1.14–1.27)
Median no. of episodes per patient [IQR] 3 [2–6] 2 [1–4]
Prior antibiotic use
None in prior year 3016 (17.3) 139,002 (33.8) 1 1
6–b12 months 1742 (10.0 65,925 (16.0) 1.23 (1.15–1.30) 1.16 (1.09–1.24)
3–b6 months 2119 (12.2) 64,301 (15.6) 1.53 (1.44–1.62) 1.37 (1.29–1.46)
1–b3 months 4368 (25.1) 83,734 (20.3) 2.37 (2.25–2.49) 1.93 (1.83–2.04)
b1 month 3.35 (3.19–3.53) 58,869 (14.3) 4.52 (4.31–4.74) 3.35 (1.00–1.11)
Comorbidities
Cardiovascular disease 3737 (21.4) 50,884 (12.4) 2.01 (1.93–2.11) 1.05 (1.00–1.10)
Diabetes 2826 (16.2) 41,404 (10.1) 1.81 (1.72–1.90) 1.12 (1.07–1.18)
Asthma 2957 (17.0) 64,973 (15.8) 1.08 (1.03–1.13) 1.07 (1.02–1.13)
Cancer 2445 (14.0) 33,451 (8.1) 1.86 (1.77–1.97) 1.15 (1.09–1.21)
Chronic kidney disease stage 3–5 3107 (17.8) 42,375 (10.3) 1.94 (1.85–2.04) 1.05 (1.00–1.11)
Initial antibiotic prescribed
Trimethoprim 7374 (45.2) 233,423 (57.3) 1 1
Nitrofurantoin 3777 (23.2) 97,428 (23.9) 1.20 (1.15–1.25) 0.96 (0.92–1.00)
Other 1384 (8.5) 25,702 (6.3) 1.77 (1.66–1.88) 1.48 (1.39–1.58)
Cephalexin 1045 (6.4) 20,987 (5.2) 1.50 (1.39–1.61) 1.15 (1.07–1.24)
Co-amoxiclav 1108 (6.8) 18,996 (4.7) 1.69 (1.57–1.81) 1.18 (1.10–1.27)
Ciproﬂoxacin 484 (3.0) 6731 (1.7) 1.95 (1.76–2.17) 1.17 (1.06–1.30)
Multiple 953 (5.9) 2590 (0.6) 13.18 (11.99–14.49) 8.98 (8.18–9.85)
Pivmecillinam 174 (1.1) 1811 (0.4) 2.79 (2.32–3.35) 1.56 (1.30–1.86)
Note: CKD, chronic renal disease; OR, adjusted odds ratios for associationswith treatment response failure during the study period frommixed effect logistic regressionmodels with gen-
eral practice and patient level random effects; Wald test p-value for association was b0.001 for all factors except for cardiovascular (p = 0.07) and chronic kidney disease (p = 0.06).
Intraclass correlation coefﬁcients for patients and practices were 0.181 and 0.009, respectively.
a Urinary tract infections (UTIs) treated with antibiotics without re-prescription.
b Ethnicity was missing for 22.5% of UTI episodes.
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nitrofurantoin (33.9%) and trimethoprim (22.2%). Three percent of epi-
sodes (n = 516) were treated with multiple antibiotics. Furthermore,
the index prescription and re-prescribed antibiotics were the same in
27.1% (pivmecillinam), 25.4% (nitrofurantoin), 22.4% (cephalexin),
20.0% (trimethoprim), 19.0% (ciproﬂoxacin) and 18.0% (co-amoxiclav)
of cases (some patients were treated with more than 1 antibiotic). Pat-
terns of antibiotic re-prescribing remained relatively stable over time
except for cephalexin and pivmecillinam. The proportion of re-
prescriptions with cephalexin decreased from 17.4% in 2011 to 13.5%
in 2015 in women, and from 11.6% to 9.1%, respectively, in men. In con-
trast, the proportion treated with pivmecillinam increased over time
from 1.4% in 2011 to 4.3% in 2015 in women, and from 1.0% to 3.8%, re-
spectively, in men.
4. Discussion
In this large cohort of patients diagnosed with lower UTI in primary
care practices in England, we found that the great majority (four out ofPlease cite this article as: M. Pujades-Rodriguez, R.M. West, M.H.Wilcox, e
Factors for Antibiotic Re-prescription..., , https://doi.org/10.1016/j.eclinm.ﬁve) received empirical antibiotic therapy on the day of diagnosis, and
most (83%) had no evidence of urine sample collection for microbiolog-
ical investigation in their electronic health records. Recent exposure to
antibiotics was common in all patient groups and was associated with
an increased risk of antibiotic re-prescription. In line with national
guidelines, there was little diversity in treatment, which was generally
limited to two antibiotics, trimethoprim and nitrofurantoin (24% and
56%, respectively). Antibiotic re-prescription was uncommon (4.1% of
UTI episodes).
This studywas based on the analysis of data collected as part of rou-
tine clinical primary care practice, and was therefore not speciﬁcally
gathered for research purposes.We identiﬁed an unselected population
of all patient groups diagnosed with lower UTI in ResearchOne primary
care practices in England, which enabled us to describe the manage-
ment and outcomes of all groups of patients identiﬁed in current clinical
guidelines for the management of UTIs. We did not restrict the analysis
to microbiologically conﬁrmed episodes because our aim was to de-
scribe the real-world management in the primary care setting. We
also did not investigate the role of urinary dipstick examination,t al., Lower Urinary Tract Infections: Management, Outcomes and Risk
2019.07.012
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guideline-deﬁned patient groups and found a low number of UTIs in pa-
tients with catheters. It is possible that some infections diagnosed in pa-
tients with catheters were coded using generic diagnostic codes and
were therefore classiﬁed in other patient groups (e.g. adults aged
65 years or above). The percentage of patients with recurrent UTIs
(more than one episode per year) ranged from 9.0% for men aged
18–64 years to 20.8% for women aged ≥65 years, and the percentages
with three or more episodes per year ranged from 1.0% to 2.6%, respec-
tively. These ﬁgures are comparable with those found in a population-
based survey conducted in England, which found that 3% of women
aged N15 years reported at least three UTIs in the previous year [2]. A
Canadian surveillance study also recorded that 14% of people with UTI
had more than one episode of infection during a 2-year period [16].
The data therefore appear consistent with other relevant studies. A
strength of our study is the longitudinal individual-patient data from
390 primary care practices geographically spread across England. This
allowed the examination of temporal associations with prescribing.
This risk factor analysis accounted for the diagnosis of multiple UTI ep-
isodeswithin patients and for the speciﬁc general practices inwhich the
patients were treated. We were unable to account for antibiotic resis-
tance per se and some factors that have been found to be associated
with resistance, including recent hospital admissions (and antibiotics
administered during admissions) [17], use of invasive procedures in
health-care settings, or care home residence [17]. Furthermore, we
were unable to evaluate dose–response associations because of the
lack of information on antibiotic dose and duration in the dataset. In ad-
dition, our study did not exclude patients with other infections, so it is
therefore impossible to completely rule out that some of the antibiotic
prescriptions were administered to treat a concomitant non-UTI
infection.
Overall, 86% of UTIs were treated with a same-day antibiotic pre-
scription, reﬂecting routine clinical practice in primary care, with deci-
sions likely based on the report of typical symptoms with or without
ﬁndings of dipstick urine testing. The proportion of patients being of-
fered delayed prescriptions or symptomatic treatment and follow-up
[18] would seems to be low, and there may be more opportunity to re-
duce empirical therapy, as undertaken in the Netherlands [3]. Initial
treatment comprised just 2 antibiotics, nitrofurantoin and trimetho-
prim, thus, prescribing in general follows national guidance for situation
when the risk of resistance is considered to be low [6,13]. NICE considers
administration of antibiotic therapy in the previous 3 months as a risk
factor for trimethoprim resistance. In our study, the median time since
last prior antibiotic prescription was 4 months.
Antibiotic resistance is a major threat to human health and calls for
action to address this threat are widespread. The UK Chief Medical
Ofﬁcer's (CMO's) annual report 2011 highlighted the importance of an-
timicrobial resistance and the need to reduce its impact [11]. A ﬁve year
antimicrobial resistance strategy was published in 2013 that proposed
potential means of ‘conserving and stewarding’ the effectiveness of
existing antimicrobial treatments [19]. A theoretical way of reducing
the emergence and spread of antibiotic resistance is to introduce more
variation (i.e. diversity) into antibiotic prescribing [20,21]. We have
conﬁrmed that there is little diversity in prescribing for UTIs, but intro-
ducing greater varietywould oppose current clinical guidelines and pre-
scribing practice.
A urine sample for microbiological investigation is recommended in
all children under 3 months [22], all children under 16 [6], pregnant
women [13] and all men [18]. An annual average increase in urine sam-
pling for culture of 3% has been reported [23]. We found that microbio-
logical investigation is not being carried out as recommended. However,
even if microbiological examination and/or culture were coded for one
in four of all episodes of UTI in patients older than 3 months, we cannot
exclude lack of recording of this information by some GPs.
As in previous studies [1–4], we investigated antibiotic re-
prescription as a measure of treatment effectiveness. Because thisPlease cite this article as: M. Pujades-Rodriguez, R.M. West, M.H.Wilcox, e
Factors for Antibiotic Re-prescription..., , https://doi.org/10.1016/j.eclinm.approach has limitations, we used different deﬁnitions of re-
prescription (the earliest subsequent prescription of a UTI-speciﬁc anti-
biotic issued within 4–28 days after the initial antibiotic prescription in
the primary analysis; andwithin 6–28 and 8–28 days in sensitivity anal-
yses). However, because of lack of linkage to hospital and emergency
services, we did not consider progression of UTI to pyelonephritis and
sepsis in the deﬁnition of re-prescription and might have missed some
events. The percentage of patients re-prescribed antibiotics after an
index prescription for the same UTI episode was low (3–4%), but this
still represents over 3000 patients each year. We also found evidence
of a statistically signiﬁcant, gradual increase in antibiotic re-
prescription over the ﬁve years covered by the study. Previous studies
have reported rates ranging between 2% when failure requiring
hospitalisation was studied in a population-based study in Taiwan
[24] to 39% amongst women treated with fosfomycin in a multinational
randomised clinical trial [25]. In our study, the risk of antibiotic re-
prescriptionwas higher in older patients,men, thosewithwhite ethnic-
ity, those recently prescribed antibiotics and those not treated with tri-
methoprim or nitrofurantoin. The random effects for patient and
practice showed that there was only a small practice effect and a more
substantial patient effect consistent with the development of resistance
within patients. Themedian time between ﬁrst and second date of anti-
biotic prescription was 11 days, whichmakes it unlikely that allergy/in-
tolerance to the ﬁrst prescription explained the second. This was
conﬁrmed by an analysis of recorded data on drug allergy and intoler-
ance. One reason for antibiotic re-prescription might be infection with
a resistant pathogen, the relationship between prior recent antibiotics
and re-prescription supports this hypothesis. In men, the presence of
prostatitis,might account for treatment failure. The association between
white ethnicity and antibiotic re-prescribing suggests that theremay be
cultural health seeking behaviours affecting prescribing, which may
warrant further investigation. Non-compliancewith the index prescrip-
tion is another possible reason for treatment failure, one that we could
not assess. Indeed, in a population-based survey in England, 63% of
women prescribed antibiotics for a recent UTI reported taking them as
prescribed [2]. The risk factors for antibiotic re-prescribing identiﬁed
in our cohort are consistent with those reported in studies of treatment
response failure [26–28] and of antibiotic resistance in the community,
including the higher risk of antibiotic-resistance [8,9,29,30] and multi-
drug resistance [31] associatedwith recent antibiotic exposure. A recent
surveillance study based on the patient-level analysis of community
urine isolates in Scotland also reported an increased risk of multidrug
resistance associated with higher cumulative exposure to total antibi-
otic, nitrofurantoin and trimethoprim in the previous six months and
with higher numbers of antibiotic classes prescribed in the previous
year in adults [17]. This increase in risk remained after 7–9 months of
any antibiotic exposure and 10–12 months of nitrofurantoin and tri-
methoprim use. Previous studies have also reported increased risk of
antibiotic (multi)drug resistance in men [17,30], older patients [17,30]
and in those with comorbidities [17]. Furthermore, in our study we
found that antibiotic re-prescription was signiﬁcantly less likely for UTI
episodes treated with trimethoprim than for episodes treated with the
other agents used, in spite of higher rates of resistance to trimethoprim
(34% in 2012–2016) [32]. There are several possible explanations for
this ﬁnding. Firstly, trimethoprim may be more effective than the other
agents. Secondly, patients with less severe symptoms, or those who are
more likely to have self-limiting conditions are being treated with tri-
methoprim making it look like trimethoprim is more effective. Thirdly,
other antibiotics are being used for more challenging cases or those
with genuinely resistant infections, increasing the risk of antibiotic re-
prescription. The latter, seems less likely given the high percentage of pa-
tients treated with nitrofurantoin and low resistance rates to this agent.
Another explanation is that nitrofurantoin is being used in patients with
reduced renal function and is ineffective for pharmacokinetic reasons, a
theory which is supported by the increased risk of re-prescription in
chronic kidney disease. These ﬁndings warrant further investigation.t al., Lower Urinary Tract Infections: Management, Outcomes and Risk
2019.07.012
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were treated with the same antibiotic as was initially prescribed. It is il-
logical to re-prescribe the same antibiotic when treatment failure is
considered clinically and this also contradicts NICE recommendation
[6]. This ﬁnding suggests (as this was a constant phenomenon across
all antibiotics) that a substantial minority of practitioners tend to pre-
scribe according to favoured agents despite a different choice being
appropriate.
We analysed routinely collected data and found evidence of its valid-
itywhen comparedwith other types of studies. For example, in a previous
study in CPRD practices, trimethoprim was the most commonly pre-
scribed antibiotic for community acquired UTI and accounted for 50% of
prescriptions and prescriptions of nitrofurantoin increased between
2004 and 2014 [11]. In a prospective cohort study, antibiotic prescribing
at initial primary care consultation was seen in 95.1% of women with
suspected UTI aged ≥16 years in England, withmost common antibiotics:
46.1% trimethoprim and 48.7% nitrofurantoin; and 14.5% subsequent an-
tibiotic prescription (similar to ours when unrestricted to the UTI speciﬁc
list) [3]. In a population-based home survey amongst 892 randomly se-
lected women aged ≥16 years in England, 65% of participants with UTIs
reported contacting their local general practice to seek care, and of
those seen by a health professional, 25% had their urine sample sent for
laboratory analysis and 74% were prescribed an antibiotic [2].
In conclusion, there are opportunities to optimise antibiotic pre-
scribing for UTIs that could potentially reduce the risk of antibiotic resis-
tance.Most patients currently diagnosedwith lower UTI in primary care
receive same-day antibiotic treatment, without microbiological investi-
gation. There is little diversity in antibiotic treatment, which is generally
limited to two agents, trimethoprim and nitrofurantoin, reﬂecting na-
tional guidelines. The rate of antibiotic re-prescription is lowbut is grad-
ually increasing and requires further study. Approximately one in ﬁve
patientswith re-prescription receives the same antibiotic again.We rec-
ommend that practice is audited to drive down this proportion. Man-
agement of UTIs might need to consider recent antibiotic use to
minimise development of antibiotic resistance to drugs used for ﬁrst
and second line therapy.
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